Camargo Taps PhDs, Postdoctoral Researchers for Training
Camargo Pharmaceutical Services has tapped academic organizations close to its Raleigh, NC site in a unique internship program...
Camargo Pharmaceutical Services, which specializes in 505(b)(2) approval pathway drug development, has tapped academic organizations close to its Raleigh, NC site in a unique internship program. According to Duke University's postdoctoral services office, which is one university partnering with Camargo on this program, historically, PhD students and postdoctoral researchers were training for tenured faculty positions, but now only 20% of graduates with a PhD will go on to tenured academic appointments. With the decrease in academic appointments, more graduates with a PhD are looking for positions beyond academia and that includes positions in pharmaceutical research.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
